Related Experiment Video

Updated: Jul 2, 2025

Deacetylation Assays to Unravel the Interplay between Sirtuins SIRT2 and Specific Protein-substrates
14:32

Deacetylation Assays to Unravel the Interplay between Sirtuins SIRT2 and Specific Protein-substrates

Published on: February 27, 2016

8.3K

SIRT7: a novel molecular target for personalized cancer treatment?

Alessandro Ianni1,2, Poonam Kumari3, Shahriar Tarighi3

  • 1Chromatin Biology Laboratory, Josep Carreras Leukaemia Research Institute (IJC), Ctra de Can Ruti, Camí de les Escoles, Badalona, Barcelona, Catalonia, 08916, Spain. alessandro.ianni@mpi-bn.mpg.de.

Oncogene
|February 21, 2024
PubMed

Insights

SIRT7, a sirtuin enzyme, plays a dual role in cancer by influencing nucleolar functions and RNA metabolism. Understanding its unique mechanisms offers potential for novel anti-cancer therapies targeting tumorigenesis.

Area of Science:

  • Molecular Biology
  • Biochemistry
  • Oncology

Background:

  • Sirtuins are NAD+-dependent enzymes regulating cellular responses to stress.
  • SIRT7 exhibits context-dependent pro-tumorigenic and tumor-suppressive roles in cancer.
  • SIRT7 possesses unique functions in nucleolar regulation and RNA metabolism, distinguishing it from other sirtuins.

Purpose of the Study:

  • To provide a comprehensive overview of SIRT7's role in various malignancies.
  • To elucidate the molecular mechanisms underlying SIRT7's dual function in tumorigenesis.
  • To explore the therapeutic potential of targeting SIRT7 in cancer treatment.

Main Methods:

  • Literature review of studies on SIRT7 and cancer.
  • Analysis of SIRT7's molecular functions, including nucleolar regulation and RNA metabolism.
  • Discussion of SIRT7's implications in tumor initiation and progression.

Main Results:

  • SIRT7's multifaceted roles in cancer are influenced by its unique enzymatic properties.
  • Its involvement in nucleolar functions and RNA processing is critical for its oncogenic or tumor-suppressive activities.
  • Distinctive features of SIRT7 offer specific molecular targets for cancer therapy.

Conclusions:

  • SIRT7 is a key regulator in tumorigenesis with unique molecular attributes.
  • Targeting SIRT7 presents a promising strategy for developing innovative anti-cancer therapies.
  • Further research into SIRT7's mechanisms can advance cancer treatment modalities.

More Related Videos

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures07:48

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures

Published on: December 26, 2016

11.3K
Discovery of Driver Genes in Colorectal HT29-derived Cancer Stem-Like Tumorspheres06:52

Discovery of Driver Genes in Colorectal HT29-derived Cancer Stem-Like Tumorspheres

Published on: July 22, 2020

6.5K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
16.8K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
524